Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 65 entries
Sorted by: Best Match Show Resources per page
Dioxins in the Venice lagoon: Present situation, projects and recovering hypotheses.

Environmental science and pollution research international

Raccanelli S, Bonamin V.
PMID: 19104873
Environ Sci Pollut Res Int. 2000;7(3):125-9. doi: 10.1065/espr2000.06.030.

Venice is famous around the world for its uniqueness and architectural splendours, arts and the history of the "Serenissima Repubblica", as it was known in the past, but few are aware that Venice economy is strongly dependent on the...

Cite
Raccanelli S, Bonamin V. Dioxins in the Venice lagoon: Present situation, projects and recovering hypotheses. Environ Sci Pollut Res Int. 2000;7(3):125-9doi: 10.1065/espr2000.06.030.
Raccanelli, S., & Bonamin, V. (2000). Dioxins in the Venice lagoon: Present situation, projects and recovering hypotheses. Environmental science and pollution research international, 7(3), 125-9. https://doi.org/10.1065/espr2000.06.030
Raccanelli, S, and Bonamin, V. "Dioxins in the Venice lagoon: Present situation, projects and recovering hypotheses." Environmental science and pollution research international vol. 7,3 (2000): 125-9. doi: https://doi.org/10.1065/espr2000.06.030
Raccanelli S, Bonamin V. Dioxins in the Venice lagoon: Present situation, projects and recovering hypotheses. Environ Sci Pollut Res Int. 2000;7(3):125-9. doi: 10.1065/espr2000.06.030. PMID: 19104873.
Copy Download .nbib Format: NLM
Lyman-α Forest Constraints on Primordial Black Holes as Dark Matter.

Physical review letters

Murgia R, Scelfo G, Viel M, Raccanelli A.
PMID: 31491102
Phys Rev Lett. 2019 Aug 16;123(7):071102. doi: 10.1103/PhysRevLett.123.071102.

The renewed interest in the possibility that primordial black holes (PBHs) may constitute a significant part of dark matter has provided motivation for revisiting old observational constraints, as well as developing new ones. We present new limits on the...

Cite
Murgia R, Scelfo G, Viel M, et al. Lyman-α Forest Constraints on Primordial Black Holes as Dark Matter. Phys Rev Lett. 2019;123(7):071102doi: 10.1103/PhysRevLett.123.071102.
Murgia, R., Scelfo, G., Viel, M., & Raccanelli, A. (2019). Lyman-α Forest Constraints on Primordial Black Holes as Dark Matter. Physical review letters, 123(7), 071102. https://doi.org/10.1103/PhysRevLett.123.071102
Murgia, Riccardo, et al. "Lyman-α Forest Constraints on Primordial Black Holes as Dark Matter." Physical review letters vol. 123,7 (2019): 071102. doi: https://doi.org/10.1103/PhysRevLett.123.071102
Murgia R, Scelfo G, Viel M, Raccanelli A. Lyman-α Forest Constraints on Primordial Black Holes as Dark Matter. Phys Rev Lett. 2019 Aug 16;123(7):071102. doi: 10.1103/PhysRevLett.123.071102. PMID: 31491102.
Copy Download .nbib Format: NLM
Long-term intergenerational transmission of memories of the Vajont disaster.

Psychological trauma : theory, research, practice and policy

Raccanello D, Gobbo C, Corona L, De Bona G, Hall R, Burro R.
PMID: 31697107
Psychol Trauma. 2019 Nov 07; doi: 10.1037/tra0000528. Epub 2019 Nov 07.

OBJECTIVE: Previous literature documented the traumatic consequences of exposure to disasters on psychological functioning, but little attention has been paid to the intergenerational transmission of the memory of disasters. We explored long-term effects on the memory of the Vajont...

Cite
Raccanello D, Gobbo C, Corona L, et al. Long-term intergenerational transmission of memories of the Vajont disaster. Psychol Trauma. 2019;doi: 10.1037/tra0000528.
Raccanello, D., Gobbo, C., Corona, L., De Bona, G., Hall, R., & Burro, R. (2019). Long-term intergenerational transmission of memories of the Vajont disaster. Psychological trauma : theory, research, practice and policy, . https://doi.org/10.1037/tra0000528
Raccanello, Daniela, et al. "Long-term intergenerational transmission of memories of the Vajont disaster." Psychological trauma : theory, research, practice and policy vol. (2019). doi: https://doi.org/10.1037/tra0000528
Raccanello D, Gobbo C, Corona L, De Bona G, Hall R, Burro R. Long-term intergenerational transmission of memories of the Vajont disaster. Psychol Trauma. 2019 Nov 07; doi: 10.1037/tra0000528. Epub 2019 Nov 07. PMID: 31697107.
Copy Download .nbib Format: NLM
Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.

Oncotarget

Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, Menegatti E, Roccatello D.
PMID: 29989000
Oncotarget. 2018 Jun 22;9(48):28799-28804. doi: 10.18632/oncotarget.25612. eCollection 2018 Jun 22.

Minimal change disease (MCD) accounts for 15% of adult nephrotic syndrome (NS) cases. Adult-MCD patients may have more severe clinical features than pediatric patients. In children, Rituximab (RTX) has been used since 2006 to treat frequently relapsing NS. In...

Cite
Fenoglio R, Sciascia S, Beltrame G, et al. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018;9(48):28799-28804doi: 10.18632/oncotarget.25612.
Fenoglio, R., Sciascia, S., Beltrame, G., Mesiano, P., Ferro, M., Quattrocchio, G., Menegatti, E., & Roccatello, D. (2018). Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget, 9(48), 28799-28804. https://doi.org/10.18632/oncotarget.25612
Fenoglio, Roberta, et al. "Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome." Oncotarget vol. 9,48 (2018): 28799-28804. doi: https://doi.org/10.18632/oncotarget.25612
Fenoglio R, Sciascia S, Beltrame G, Mesiano P, Ferro M, Quattrocchio G, Menegatti E, Roccatello D. Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome. Oncotarget. 2018 Jun 22;9(48):28799-28804. doi: 10.18632/oncotarget.25612. eCollection 2018 Jun 22. PMID: 29989000; PMCID: PMC6034752.
Copy Download .nbib Format: NLM
Pathogenesis-based new perspectives of management of ANCA-associated vasculitis.

Autoimmunity reviews

Sciascia S, Ponticelli C, Roccatello D.
PMID: 34971805
Autoimmun Rev. 2021 Dec 28;103030. doi: 10.1016/j.autrev.2021.103030. Epub 2021 Dec 28.

While the pathogenesis of anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) is still not fully elucidated, there is a mounting evidence that it is initiated by inflammation and activation of innate immunity in the presence of predisposing factors, innate immunity,...

Cite
Sciascia S, Ponticelli C, Roccatello D. Pathogenesis-based new perspectives of management of ANCA-associated vasculitis. Autoimmun Rev. 2021;103030doi: 10.1016/j.autrev.2021.103030.
Sciascia, S., Ponticelli, C., & Roccatello, D. (2021). Pathogenesis-based new perspectives of management of ANCA-associated vasculitis. Autoimmunity reviews, 103030. https://doi.org/10.1016/j.autrev.2021.103030
Sciascia, Savino, et al. "Pathogenesis-based new perspectives of management of ANCA-associated vasculitis." Autoimmunity reviews vol. (2021): 103030. doi: https://doi.org/10.1016/j.autrev.2021.103030
Sciascia S, Ponticelli C, Roccatello D. Pathogenesis-based new perspectives of management of ANCA-associated vasculitis. Autoimmun Rev. 2021 Dec 28;103030. doi: 10.1016/j.autrev.2021.103030. Epub 2021 Dec 28. PMID: 34971805.
Copy Download .nbib Format: NLM
Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study.

Frontiers in medicine

Sciascia S, Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Vaccarino A, Rossi D, Roccatello D.
PMID: 33598471
Front Med (Lausanne). 2021 Feb 01;8:621590. doi: 10.3389/fmed.2021.621590. eCollection 2021.

No abstract available.

Cite
Sciascia S, Radin M, Cecchi I, et al. Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. Front Med (Lausanne). 2021;8:621590doi: 10.3389/fmed.2021.621590.
Sciascia, S., Radin, M., Cecchi, I., Rubini, E., Foddai, S. G., Barinotti, A., Vaccarino, A., Rossi, D., & Roccatello, D. (2021). Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. Frontiers in medicine, 8621590. https://doi.org/10.3389/fmed.2021.621590
Sciascia, Savino, et al. "Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study." Frontiers in medicine vol. 8 (2021): 621590. doi: https://doi.org/10.3389/fmed.2021.621590
Sciascia S, Radin M, Cecchi I, Rubini E, Foddai SG, Barinotti A, Vaccarino A, Rossi D, Roccatello D. Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study. Front Med (Lausanne). 2021 Feb 01;8:621590. doi: 10.3389/fmed.2021.621590. eCollection 2021. PMID: 33598471; PMCID: PMC7882486.
Copy Download .nbib Format: NLM
Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease.

Arthritis care & research

Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, Bacco B, Rubini E, Foddai SG, Padovan M, Gallo Cassarino S, Franceschini F, Andrade D, Benedetto C, Govoni M, Bertero T, Marozio L, Roccatello D, Andreoli L, Sciascia S.
PMID: 32702197
Arthritis Care Res (Hoboken). 2021 Dec;73(12):1804-1808. doi: 10.1002/acr.24391. Epub 2021 Oct 04.

OBJECTIVE: We aimed to investigate the impact of applying the 2019 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) classification criteria for systemic lupus erythematosus (SLE) in a previously described cohort of women with undifferentiated connective...

Cite
Radin M, Schreiber K, Cecchi I, et al. Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Arthritis Care Res (Hoboken). 2021;73(12):1804-1808doi: 10.1002/acr.24391.
Radin, M., Schreiber, K., Cecchi, I., Bortoluzzi, A., Crisafulli, F., de Freitas, C. M., Bacco, B., Rubini, E., Foddai, S. G., Padovan, M., Gallo Cassarino, S., Franceschini, F., Andrade, D., Benedetto, C., Govoni, M., Bertero, T., Marozio, L., Roccatello, D., Andreoli, L., & Sciascia, S. (2021). Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Arthritis care & research, 73(12), 1804-1808. https://doi.org/10.1002/acr.24391
Radin, Massimo, et al. "Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease." Arthritis care & research vol. 73,12 (2021): 1804-1808. doi: https://doi.org/10.1002/acr.24391
Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM, Bacco B, Rubini E, Foddai SG, Padovan M, Gallo Cassarino S, Franceschini F, Andrade D, Benedetto C, Govoni M, Bertero T, Marozio L, Roccatello D, Andreoli L, Sciascia S. Impact of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Multicenter Cohort Study of 133 Women With Undifferentiated Connective Tissue Disease. Arthritis Care Res (Hoboken). 2021 Dec;73(12):1804-1808. doi: 10.1002/acr.24391. Epub 2021 Oct 04. PMID: 32702197.
Copy Download .nbib Format: NLM
A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response.

Journal of clinical medicine

Rossi D, Sciascia S, Cecchi I, Saracco M, Montabone E, Modena V, Pellerito R, Carignola R, Roccatello D.
PMID: 33466837
J Clin Med. 2021 Jan 14;10(2). doi: 10.3390/jcm10020292.

BACKGROUND: B-cells have been suggested to play a role in the pathogenesis of systemic sclerosis (SSc), representing, therefore, a potential therapeutic target.OBJECTIVES: We aimed at investigating the 36-month outcomes of 20 SSc patients who underwent an intensified B-depletion therapy...

Cite
Rossi D, Sciascia S, Cecchi I, et al. A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. J Clin Med. 2021;10(2)doi: 10.3390/jcm10020292.
Rossi, D., Sciascia, S., Cecchi, I., Saracco, M., Montabone, E., Modena, V., Pellerito, R., Carignola, R., & Roccatello, D. (2021). A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. Journal of clinical medicine, 10(2), . https://doi.org/10.3390/jcm10020292
Rossi, Daniela, et al. "A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response." Journal of clinical medicine vol. 10,2 (2021). doi: https://doi.org/10.3390/jcm10020292
Rossi D, Sciascia S, Cecchi I, Saracco M, Montabone E, Modena V, Pellerito R, Carignola R, Roccatello D. A 3-Year Observational Study of Patients with Progressive Systemic Sclerosis Treated with an Intensified B Lymphocyte Depletion Protocol: Clinical and Immunological Response. J Clin Med. 2021 Jan 14;10(2). doi: 10.3390/jcm10020292. PMID: 33466837; PMCID: PMC7830314.
Copy Download .nbib Format: NLM
Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians.

The Lancet. Rheumatology

Schreiber K, Sciascia S, Bruce IN, Giles I, Cuadrado MJ, Cohen H, Gordon C, Isenberg D, Jacobsen S, Middeldorp S, Mosca M, Pavord S, Radin M, Roccatello D, Salmon J, Vinet E, Voss A, Watkins L, Hunt BJ.
PMID: 33163976
Lancet Rheumatol. 2020 Dec;2(12):e735-e736. doi: 10.1016/S2665-9913(20)30382-9. Epub 2020 Oct 29.

No abstract available.

Cite
Schreiber K, Sciascia S, Bruce IN, et al. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. Lancet Rheumatol. 2020;2(12):e735-e736doi: 10.1016/S2665-9913(20)30382-9.
Schreiber, K., Sciascia, S., Bruce, I. N., Giles, I., Cuadrado, M. J., Cohen, H., Gordon, C., Isenberg, D., Jacobsen, S., Middeldorp, S., Mosca, M., Pavord, S., Radin, M., Roccatello, D., Salmon, J., Vinet, E., Voss, A., Watkins, L., & Hunt, B. J. (2020). Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. The Lancet. Rheumatology, 2(12), e735-e736. https://doi.org/10.1016/S2665-9913(20)30382-9
Schreiber, Karen, et al. "Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians." The Lancet. Rheumatology vol. 2,12 (2020): e735-e736. doi: https://doi.org/10.1016/S2665-9913(20)30382-9
Schreiber K, Sciascia S, Bruce IN, Giles I, Cuadrado MJ, Cohen H, Gordon C, Isenberg D, Jacobsen S, Middeldorp S, Mosca M, Pavord S, Radin M, Roccatello D, Salmon J, Vinet E, Voss A, Watkins L, Hunt BJ. Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. Lancet Rheumatol. 2020 Dec;2(12):e735-e736. doi: 10.1016/S2665-9913(20)30382-9. Epub 2020 Oct 29. PMID: 33163976; PMCID: PMC7598898.
Copy Download .nbib Format: NLM
Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.

Journal of clinical medicine

Roccatello D, Fenoglio R, Naretto C, Baldovino S, Sciascia S, Ferro M, Rossi D.
PMID: 33050272
J Clin Med. 2020 Oct 09;9(10). doi: 10.3390/jcm9103232.

OBJECTIVES: This paper aims to describe the clinical experience with Daratumumab (DARA), a first-in-class anti-CD38 human monoclonal IgG1κ antibody monotherapy, in severe patients with AL and biopsy-proven renal involvement. Immunoglobulin light chain (AL) amyloidosis with multi-organ involvement is characterized...

Cite
Roccatello D, Fenoglio R, Naretto C, et al. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. J Clin Med. 2020;9(10)doi: 10.3390/jcm9103232.
Roccatello, D., Fenoglio, R., Naretto, C., Baldovino, S., Sciascia, S., Ferro, M., & Rossi, D. (2020). Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. Journal of clinical medicine, 9(10), . https://doi.org/10.3390/jcm9103232
Roccatello, Dario, et al. "Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience." Journal of clinical medicine vol. 9,10 (2020). doi: https://doi.org/10.3390/jcm9103232
Roccatello D, Fenoglio R, Naretto C, Baldovino S, Sciascia S, Ferro M, Rossi D. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience. J Clin Med. 2020 Oct 09;9(10). doi: 10.3390/jcm9103232. PMID: 33050272; PMCID: PMC7600836.
Copy Download .nbib Format: NLM
A focus on rare and complex kidney diseases.

Journal of nephrology

Roccatello D.
PMID: 32062773
J Nephrol. 2020 Apr;33(2):199. doi: 10.1007/s40620-020-00710-7.

No abstract available.

Cite
Roccatello D. A focus on rare and complex kidney diseases. J Nephrol. 2020;33(2):199doi: 10.1007/s40620-020-00710-7.
Roccatello, D. (2020). A focus on rare and complex kidney diseases. Journal of nephrology, 33(2), 199. https://doi.org/10.1007/s40620-020-00710-7
Roccatello, Dario. "A focus on rare and complex kidney diseases." Journal of nephrology vol. 33,2 (2020): 199. doi: https://doi.org/10.1007/s40620-020-00710-7
Roccatello D. A focus on rare and complex kidney diseases. J Nephrol. 2020 Apr;33(2):199. doi: 10.1007/s40620-020-00710-7. PMID: 32062773.
Copy Download .nbib Format: NLM
IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients.

Frontiers in medicine

Sciascia S, Cecchi I, Radin M, Rubini E, Suárez A, Roccatello D, Rodríguez-Carrio J.
PMID: 31612138
Front Med (Lausanne). 2019 Sep 26;6:211. doi: 10.3389/fmed.2019.00211. eCollection 2019.

No abstract available.

Cite
Sciascia S, Cecchi I, Radin M, et al. IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. Front Med (Lausanne). 2019;6:211doi: 10.3389/fmed.2019.00211.
Sciascia, S., Cecchi, I., Radin, M., Rubini, E., Suárez, A., Roccatello, D., & Rodríguez-Carrio, J. (2019). IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. Frontiers in medicine, 6211. https://doi.org/10.3389/fmed.2019.00211
Sciascia, Savino, et al. "IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients." Frontiers in medicine vol. 6 (2019): 211. doi: https://doi.org/10.3389/fmed.2019.00211
Sciascia S, Cecchi I, Radin M, Rubini E, Suárez A, Roccatello D, Rodríguez-Carrio J. IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients. Front Med (Lausanne). 2019 Sep 26;6:211. doi: 10.3389/fmed.2019.00211. eCollection 2019. PMID: 31612138; PMCID: PMC6775216.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 65 entries